Form 4 for MLTX MoonLake Immunotherapeutics

Accepted 2026-07-13 16:10:17 ET · period of report 2026-07-09 · accession 0001213900-26-077564 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MT	2026-07-13 16:10	2026-07-09+	MLTX	Santos da Silva Jorge	CEO, Dir	S - Sale	$20.02	-102.2K	2.77M	-4%	-$2.05M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A ordinary shares, par value $0.0001 per share	2026-07-09	S	D	33,936	$20.01	2,843,182	D	—	—	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2	Common	Class A ordinary shares, par value $0.0001 per share	2026-07-10	S	D	68,289	$20.02	2,774,893	D	—	—	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.